NEW YORK (GenomeWeb) – A large-scale analysis of almost 51,000 exomes of patients and their electronic health records by the Regeneron Genetics Center and the Geisinger Health System has revealed clinically actionable variants in 3.5 percent of individuals as well as a number of known and potential drug targets.

The study also demonstrated that exome sequencing can identify individuals at risk of familial hypercholesterolemia (FH), providing an example of the potential clinical benefit of planned similar large-scale sequencing studies, such as the Precision Medicine Initiative.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Sponsored by

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Sponsored by

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sponsored by

This webinar will discuss an approach for automating variant classification based on the American College of Medical Genetics and Genomics guidelines.

Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.